Literature DB >> 21125354

Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments.

Evanthia Galanis1, Wenting Wu, Jann Sarkaria, Susan M Chang, Howard Colman, Daniel Sargent, David A Reardon.   

Abstract

Advances in molecular genetics have aided the identification of potential biomarkers with significant clinical promise in neurooncology. These advances and the evolution of targeted therapeutics necessitate the development and incorporation of innovative clinical trial designs that can effectively validate and assess the clinical utility of biomarkers. In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21125354      PMCID： PMC3155285          DOI： 10.1007/s11912-010-0144-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  28 in total

1.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Authors:  J S Smith; A Perry; T J Borell; H K Lee; J O'Fallon; S M Hosek; D Kimmel; A Yates; P C Burger; B W Scheithauer; R B Jenkins
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.

Authors:  Robert B Jenkins; Hilary Blair; Karla V Ballman; Caterina Giannini; Robert M Arusell; Mark Law; Heather Flynn; Sandra Passe; Sara Felten; Paul D Brown; Edward G Shaw; Jan C Buckner
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

3.  A multigene predictor of outcome in glioblastoma.

Authors:  Howard Colman; Li Zhang; Erik P Sulman; J Matthew McDonald; Nasrin Latif Shooshtari; Andreana Rivera; Sonya Popoff; Catherine L Nutt; David N Louis; J Gregory Cairncross; Mark R Gilbert; Heidi S Phillips; Minesh P Mehta; Arnab Chakravarti; Christopher E Pelloski; Krishna Bhat; Burt G Feuerstein; Robert B Jenkins; Ken Aldape
Journal:  Neuro Oncol       Date:  2009-10-20       Impact factor: 12.300

4.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

5.  MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

Authors:  Martin J van den Bent; Hendrikus J Dubbink; Marc Sanson; Cathleen R van der Lee-Haarloo; Monika Hegi; Judith W M Jeuken; Ahmed Ibdaih; Alba A Brandes; Martin J B Taphoorn; Marc Frenay; Denis Lacombe; Thierry Gorlia; Winand N M Dinjens; Johan M Kros
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

6.  NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.

Authors:  Wolfgang Wick; Christian Hartmann; Corinna Engel; Mandy Stoffels; Jörg Felsberg; Florian Stockhammer; Michael C Sabel; Susanne Koeppen; Ralf Ketter; Richard Meyermann; Marion Rapp; Christof Meisner; Rolf D Kortmann; Torsten Pietsch; Otmar D Wiestler; Ulrike Ernemann; Michael Bamberg; Guido Reifenberger; Andreas von Deimling; Michael Weller
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

7.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Authors:  Marc Sanson; Yannick Marie; Sophie Paris; Ahmed Idbaih; Julien Laffaire; François Ducray; Soufiane El Hallani; Blandine Boisselier; Karima Mokhtari; Khe Hoang-Xuan; Jean-Yves Delattre
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

9.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

Authors:  Martin J van den Bent; Alba A Brandes; Roy Rampling; Mathilde C M Kouwenhoven; Johan M Kros; Antoine F Carpentier; Paul M Clement; Marc Frenay; Mario Campone; Jean-Francois Baurain; Jean-Paul Armand; Martin J B Taphoorn; Alicia Tosoni; Heidemarie Kletzl; Barbara Klughammer; Denis Lacombe; Thierry Gorlia
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

10.  A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.

Authors:  Ian A Cree; Christian M Kurbacher; Alan Lamont; Andrew C Hindley; Sharon Love
Journal:  Anticancer Drugs       Date:  2007-10       Impact factor: 2.248
View more
  9 in total

Review 1.  Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2.

Authors:  Brian M Alexander; Patrick Y Wen; Lorenzo Trippa; David A Reardon; Wai-Kwan Alfred Yung; Giovanni Parmigiani; Donald A Berry
Journal:  Neuro Oncol       Date:  2013-07-14       Impact factor: 12.300

Review 2.  Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Authors:  Miranta Antoniou; Ruwanthi Kolamunnage-Dona; Andrea L Jorgensen
Journal:  J Pers Med       Date:  2017-01-25

3.  Frontiers in Suicide Gene Therapy of Cancer.

Authors:  Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2012-10-22

Review 4.  Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions.

Authors:  Michal Bienkowski; Anna S Berghoff; Christine Marosi; Adelheid Wöhrer; Harald Heinzl; Johannes A Hainfellner; Matthias Preusser
Journal:  Clin Neuropathol       Date:  2015 Sep-Oct       Impact factor: 1.368

Review 5.  Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.

Authors:  Harry R Haynes; Sandra Camelo-Piragua; Kathreena M Kurian
Journal:  Front Oncol       Date:  2014-03-24       Impact factor: 6.244

Review 6.  Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Authors:  Miranta Antoniou; Andrea L Jorgensen; Ruwanthi Kolamunnage-Dona
Journal:  PLoS One       Date:  2016-02-24       Impact factor: 3.240

7.  IQGAP1 in Podosomes/Invadosomes Is Involved in the Progression of Glioblastoma Multiforme Depending on the Tumor Status.

Authors:  Deborah Rotoli; Natalia Dolores Pérez-Rodríguez; Manuel Morales; María Del Carmen Maeso; Julio Ávila; Ali Mobasheri; Pablo Martín-Vasallo
Journal:  Int J Mol Sci       Date:  2017-01-13       Impact factor: 5.923

Review 8.  Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence.

Authors:  Hayley P Ellis; Mark Greenslade; Ben Powell; Inmaculada Spiteri; Andrea Sottoriva; Kathreena M Kurian
Journal:  Front Oncol       Date:  2015-11-16       Impact factor: 6.244

9.  BICD1 expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas.

Authors:  Shang-Pen Huang; Yu-Chan Chang; Qie Hua Low; Alexander T H Wu; Chi-Long Chen; Yuan-Feng Lin; Michael Hsiao
Journal:  Oncotarget       Date:  2017-11-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.